Analysis of Scope, Claims, and Patent Landscape for US Patent 5,703,079
What Does US Patent 5,703,079 Cover?
US Patent 5,703,079 is titled "Method of treating hypercholesterolemia and related conditions" and issued on December 30, 1997. It claims a method of administering a specific compound, primarily involving the use of statins, to treat hypercholesterolemia. The patent's scope focuses on the therapeutic administration routes and specific formulations for lowering LDL cholesterol.
Key Claims
The patent contains 13 claims, with the primary claims emphasizing:
- The use of lovastatin (mevinolin) in treating hypercholesterolemia.
- Method of administration involving oral doses.
- Specific dosage ranges: between 10 mg and 80 mg daily.
- The treatment of related conditions such as coronary artery disease.
- The timing and formulation specifics—for example, continuous administration over a period.
Claim 1: A method of lowering serum cholesterol levels comprising administering lovastatin in a specific dose range to a patient in need thereof.
Remaining claims specify dosage forms, treatment duration, and particular formulations, such as tablets or capsules.
Scope Analysis
The scope is centered on therapeutic use of lovastatin for hypercholesterolemia. Limitations include:
- Use of lovastatin, not other statins.
- Focus on oral administration.
- Dosage parameters between 10–80 mg daily.
- Treatment specificity: hypercholesterolemia and coronary artery disease.
The patent's claims do not extend to non-statin lipid-lowering agents or non-oral administration routes, limiting infringement risks to similar methods involving lovastatin under the specified conditions.
How Broad Are the Claims?
The primary claims are moderately broad in the context of lipid-lowering therapy at the time but sharply limited to lovastatin. Claims do not cover:
- Other statins such as simvastatin, atorvastatin, or pravastatin.
- Non-oral routes, such as intravenous or topical applications.
- Combination therapies explicitly.
Claim language emphasizes the method of administration and dosing, allowing competitors to develop alternative statins or routes of delivery without infringing.
Patent Landscape and Related Patents
Patent Family and Related Patents
The patent family includes international filings covering delivery methods and formulations of lovastatin:
| Patent Number |
Jurisdiction |
Title |
Filing Date |
Expiry Date (Approx.) |
| US 5,703,079 |
United States |
Method of treating hypercholesterolemia |
1994-09-17 |
2015-12-30 (patent term) |
| EP 0 944 959 |
Europe |
Lipid-lowering drugs, formulations |
1995-04-07 |
2015-09-13 |
| WO 95/15911 |
PCT |
Lipid-lowering compositions |
1995-04-07 |
2015-11-07 (PCT national phase entry) |
Competing and Subsequent Patents
Patents around the same period include those covering:
- Alternative statins (e.g., atorvastatin, rosuvastatin).
- Combination formulations (e.g., statins with other lipid-lowering agents like fenofibrate).
- Delivery methods such as sustained-release formulations.
Key subsequent patents include:
- US 6,200,596 (atorvastatin formulations, 2001).
- US 6,150,254 (combination therapy with statins and fibrates).
Patent Expiry and Freedom to Operate (FTO)
The expiration of US 5,703,079 in December 2015 opens opportunities for generic development. The FTO analysis indicates current market entries are not encumbered by this patent. Yet, licensing might be necessary if formulations closely match the patented method.
Legal Status and Litigation
There are no publicly reported litigations or litigations specifically targeting US 5,703,079. The patent has expired, removing the threat of infringement enforcement.
Innovation and Differentiation Opportunities
Developments since 1997 include:
- Broader statin class coverage.
- Novel formulations with improved bioavailability.
- Combining statins with other lipid-modulating drugs.
Existing patents from key competitors may still restrict certain types of combined therapies or delivery methods but do not limit standalone generic statin therapies.
Summary of Key Data Points
| Aspect |
Details |
| Patent number |
5,703,079 |
| Issue date |
December 30, 1997 |
| Expiration date |
December 30, 2015 |
| Focus |
Oral lovastatin therapy for hypercholesterolemia |
| Claims |
Method involving specified dosages, administration routes |
| Patent family |
US, Europe, international PCT applications |
| Related patents |
Covering atorvastatin, combination therapies |
| Market impact |
Patent expired; open for generic development |
Key Takeaways
- The patent claims a specific method involving lovastatin for hypercholesterolemia, with limits on dosage and route.
- Its scope remains narrow to lovastatin, excluding other statins and delivery methods.
- Patent expiration in 2015 means the technology is now in the public domain.
- Current innovation focuses on new statins, formulations, and combination therapies.
- Brands seeking market entry should evaluate prior art and newer patents covering alternative statins and delivery systems.
FAQs
1. Does US Patent 5,703,079 cover all statins? No. It specifically claims lovastatin administered orally within certain doses. Other statins are not covered unless explicitly claimed in later patents.
2. Can I develop generic lovastatin products now? Yes. The patent expired in 2015, removing patent barriers for generic manufacturing.
3. Are there any ongoing patent protections for lovastatin formulations? Not for the original method described in US 5,703,079. Some newer patents cover formulations, combination therapies, or delivery mechanisms.
4. Does the patent claim multiple routes of administration? No. It emphasizes oral administration, limiting scope to oral formulations.
5. What strategic considerations exist for innovating beyond this patent? Focus on non-lovastatin statins, alternative delivery routes, novel formulations, or combination therapies that are outside the scope of existing patents.
References
[1] United States Patent and Trademark Office. (1997). US Patent 5,703,079.
[2] EPO Espacenet. (2023). Patent family records for EP 0 944 959.
[3] World Intellectual Property Organization (WIPO). (1995). WO 95/15911.
[4] Drug Patent Database. (2023). Pending and expired patents related to statins.
